Press Releases

Date Title
January 28, 2021
Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million
MONMOUTH JUNCTION, N.J. , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications,
January 28, 2021
Outlook Therapeutics Announces $10.0 Million Bought Deal Offering of Common Stock
MONMOUTH JUNCTION, N.J. , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today
January 12, 2021
Leading Ophthalmology Organization Launches Podcast Video with Firas Rahhal, MD, to Explore the Genesis and Promise of Outlook Therapeutics’ ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Leading retina clinician Dr. Rahhal discusses the market need for an FDA-approved ophthalmic bevacizumab for treating wet AMD and other retinal diseases Terry Dagnon , COO, and Jeff Evanson , CCO, of Outlook Therapeutics share the clinical rationale and regulatory framework for developing ONS-5010
January 5, 2021
Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
MONMOUTH JUNCTION, N.J. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence
December 23, 2020
Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update
All planned clinical trials for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) wet AMD BLA now fully enrolled or completed Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration trial for ONS-5010 (NORSE TWO) with new BLA filing expected in second half of 2021 MONMOUTH
December 1, 2020
Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
MONMOUTH JUNCTION, N.J. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced today that it has received
November 19, 2020
Outlook Therapeutics Announces Creation of Global Retina Advisory Council
Advisory Co uncil to collaborate on ou t reach to retinal clinicians to support development and commercialization of ONS-5010, an investigational ophthalmic formulation of bevac i zumab MONMOUTH JUNCTION, N.J. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.
November 11, 2020
Virtual KOL Roundtable Recap: Outlook Therapeutics and Firas Rahhal, MD, Discussed wet AMD Treatment Landscape and ONS-5010/LYTENAVA™
Dr. Rahhal , a leading retinal clinician,   offer ed   insight on wet AMD treatment and the p otential of ONS-5010/ LYTENA VA ™ (bevacizumab-vikg) , if approved, to improve available treatment options Outlook Therapeutics detail ed   ongoing development and pre- commercial planning of ONS-5010/
November 5, 2020
Outlook Therapeutics Secures $10 Million in Additional Working Capital
MONMOUTH JUNCTION, N.J. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the issuance of
November 3, 2020
Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Full enrollment of 195   subjects in NORSE THREE achieved in less than one month, significantly ahead of schedule All planned clinical trials for ONS-5010/LYTENAVA ™ BLA for wet AMD now fully enrolled or completed Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration
Displaying 31 - 40 of 136